Stay updated with breaking news from Primary Membranous. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Previously, felzartamab received orphan drug designation and breakthrough therapy designation for the treatment of primary membranous nephropathy.
Positive phase 2 data from 2 studies on the investigational monoclonal antibody felzartamab designed to deplete CD38+ plasma cells, demonstrated reduced pathogenic antibody levels in primary membranous nephropathy.
Research into some of the world’s rarest forms of cancer and disease have received a boost, with the Morrison Government announcing 27 grant